H.C. Wainwright downgraded Esperion (ESPR) to Neutral from Buy with a $3.16 price target after the company agreed to be acquired by investment firm Archimed for for $3.16 per share.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ESPR:
- Esperion downgraded to Neutral from Overweight at Cantor Fitzgerald
- Esperion to be acquired by Archimed for $3.16 per share, one CVR
- Esperion Therapeutics: Reinforced Buy Rating on Strengthened Investment Story and Conference-Driven Upside Catalysts
- Esperion Completes Corstasis Acquisition, Expands Cardiovascular Portfolio
- Esperion, Athyrium Capital enter $50M royalty financing agreement